Association of Hormonal Contraception with Meningioma Location in Indonesian Patients
- PMID: 35345379
- PMCID: PMC9360935
- DOI: 10.31557/APJCP.2022.23.3.1047
Association of Hormonal Contraception with Meningioma Location in Indonesian Patients
Abstract
Background: Meningioma is the most common primary intracranial tumor. Previous studies have shown the possible association between hormonal contraceptive use and meningioma location. Therefore, this study aimed to analyze the association between the history of hormonal contraceptive use and the location of meningioma in the Indonesian population.
Methods: In total, 99 histologically confirmed female meningioma patients admitted to Dr. Sardjito General Hospital Yogyakarta, Indonesia, were included in this study. Data on hormonal contraception and other variables were collected from medical records. Meningioma locations were determined from brain Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) scan before surgery.
Results: Seventy-two (72.7%) patients had a history of hormonal contraceptive use. The subjects consist of 83 (83.8%) WHO grade I and 16 (16.2%) WHO grade II and III tumors. A total of 57 (57.6%) tumors were located in the spheno-orbital region. We found a significant association between hormonal contraceptive use and meningioma location in the spheno-orbital region (Odds ratio (OR) 2.573, p=0.038). This resulted in the patients in the hormonal contraception group having more visual impairment (p=0.044).
Conclusion: The use of hormonal contraception is associated with the location of meningioma in the spheno-orbital region.
Keywords: Indonesian population; hormonal contraception; meningioma; meningioma location.
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
- Apra C, Roblot P, Alkhayri A, et al. Female gender and exogenous progesterone exposition as risk factors for spheno-orbital meningiomas. J Neurooncol. 2020;149:95–101. - PubMed
-
- Baldi I, Engelhardt J, Bonnet C, et al. Epidemiology of meningiomas. Neurochirurgie. 2018;64:5–14. - PubMed
-
- Bernat AL, Oyama K, Hamdi S, et al. Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir. 2015;157:1741–6. - PubMed
-
- Champeaux-Depond C, Weller J, Froelich S, Sartor A. Cyproterone acetate and meningioma: a nationwide-wide population based study. J Neurooncol. 2021;151:331–8. - PubMed
